These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 26238627)

  • 21. Immunohistochemical and molecular genetic study on epithelioid glioblastoma: Series of seven cases with review of literature.
    Khanna G; Pathak P; Suri V; Sharma MC; Chaturvedi S; Ahuja A; Bhardwaj M; Garg A; Sarkar C; Sharma R
    Pathol Res Pract; 2018 May; 214(5):679-685. PubMed ID: 29615337
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined "Infiltrating Astrocytoma/Pleomorphic Xanthoastrocytoma" Harboring IDH1 R132H and BRAF V600E Mutations.
    Yamada S; Kipp BR; Voss JS; Giannini C; Raghunathan A
    Am J Surg Pathol; 2016 Feb; 40(2):279-84. PubMed ID: 26414224
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of Histomorphologic/Molecular Association and Immune Checkpoint Regulators in Epithelioid Glioblastoma and Pleomorphic Xanthoastrocytoma: Are These Tumors Potential Candidates for Immune Checkpoint Blockade?
    Mahajan S; Singh J; Dandapath I; Jha P; Chaturvedi S; Ahuja A; Bhardwaj M; Saran R; Garg A; Sharma MC; Manjunath N; Suri A; Sarkar C; Suri V
    Appl Immunohistochem Mol Morphol; 2024 Feb; 32(2):84-95. PubMed ID: 38158760
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of WHO 2016 update of brain tumor classification, molecular markers and clinical outcomes in pleomorphic xanthoastrocytoma.
    Tonse R; Gupta T; Epari S; Shastri JG; Gurav M; Bano N; Jalali R
    J Neurooncol; 2018 Jan; 136(2):343-350. PubMed ID: 29147864
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications.
    Dias-Santagata D; Lam Q; Vernovsky K; Vena N; Lennerz JK; Borger DR; Batchelor TT; Ligon KL; Iafrate AJ; Ligon AH; Louis DN; Santagata S
    PLoS One; 2011 Mar; 6(3):e17948. PubMed ID: 21479234
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PI3K/AKT pathway alterations are associated with clinically aggressive and histologically anaplastic subsets of pilocytic astrocytoma.
    Rodriguez EF; Scheithauer BW; Giannini C; Rynearson A; Cen L; Hoesley B; Gilmer-Flynn H; Sarkaria JN; Jenkins S; Long J; Rodriguez FJ
    Acta Neuropathol; 2011 Mar; 121(3):407-20. PubMed ID: 21113787
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dysembryoplastic neuroepithelial tumors share with pleomorphic xanthoastrocytomas and gangliogliomas BRAF(V600E) mutation and expression.
    Chappé C; Padovani L; Scavarda D; Forest F; Nanni-Metellus I; Loundou A; Mercurio S; Fina F; Lena G; Colin C; Figarella-Branger D
    Brain Pathol; 2013 Sep; 23(5):574-83. PubMed ID: 23442159
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The evolution of pleomorphic xanthoastrocytoma: from genesis to molecular alterations and mimics.
    Mahajan S; Dandapath I; Garg A; Sharma MC; Suri V; Sarkar C
    Lab Invest; 2022 Jul; 102(7):670-681. PubMed ID: 35031693
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BRAF V600E, TERT promoter mutations and CDKN2A/B homozygous deletions are frequent in epithelioid glioblastomas: a histological and molecular analysis focusing on intratumoral heterogeneity.
    Nakajima N; Nobusawa S; Nakata S; Nakada M; Yamazaki T; Matsumura N; Harada K; Matsuda H; Funata N; Nagai S; Nakamura H; Sasaki A; Akimoto J; Hirato J; Yokoo H
    Brain Pathol; 2018 Sep; 28(5):663-673. PubMed ID: 29105198
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Composite pleomorphic xanthoastrocytoma-epithelioid glioneuronal tumor with BRAF V600E mutation - report of three cases.
    Aisner DL; Newell KL; Pollack AG; Kleinschmidt-Demasters BK; Steinberg GK; Smyth LT; Vogel H
    Clin Neuropathol; 2014; 33(2):112-21. PubMed ID: 24321241
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A case of an epithelioid glioblastoma with the BRAF V600E mutation colocalized with BRAF intact low-grade diffuse astrocytoma.
    Kuroda J; Nobusawa S; Nakamura H; Yokoo H; Ueda R; Makino K; Yano S; Kuratsu J
    Neuropathology; 2016 Apr; 36(2):181-6. PubMed ID: 26375727
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BRAF VE1 immunoreactivity patterns in epithelioid glioblastomas positive for BRAF V600E mutation.
    Kleinschmidt-DeMasters BK; Aisner DL; Foreman NK
    Am J Surg Pathol; 2015 Apr; 39(4):528-40. PubMed ID: 25581727
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anaplastic PXA in adults: case series with clinicopathologic and molecular features.
    Schmidt Y; Kleinschmidt-DeMasters BK; Aisner DL; Lillehei KO; Damek D
    J Neurooncol; 2013 Jan; 111(1):59-69. PubMed ID: 23096133
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular Features and Prognostic Factors of Pleomorphic Xanthoastrocytoma: A Collaborative Investigation of the Tohoku Brain Tumor Study Group.
    Ono T; Sasajima T; Shimizu H; Natsumeda M; Kanamori M; Asano K; Beppu T; Matsuda K; Ichikawa M; Fujii Y; Ohkuma H; Ogasawara K; Sonoda Y; Saito K; Nobusawa S; Nakazato Y; Kitanaka C; Kayama T; Tominaga T;
    Neurol Med Chir (Tokyo); 2020 Nov; 60(11):543-552. PubMed ID: 33071274
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical, Morphological, and Molecular Study on Grade 2 and 3 Pleomorphic Xanthoastrocytoma.
    Zhang H; Ma XJ; Xiang XP; Wang QY; Tang JL; Yu XY; Xu JH
    Curr Oncol; 2023 Feb; 30(2):2405-2416. PubMed ID: 36826144
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Morphological and molecular features of astroblastoma, including BRAFV600E mutations, suggest an ontological relationship to other cortical-based gliomas of children and young adults.
    Lehman NL; Hattab EM; Mobley BC; Usubalieva A; Schniederjan MJ; McLendon RE; Paulus W; Rushing EJ; Georgescu MM; Couce M; Dulai MS; Cohen ML; Pierson CR; Raisanen JM; Martin SE; Lehman TD; Lipp ES; Bonnin JM; Al-Abbadi MA; Kenworthy K; Zhao K; Mohamed N; Zhang G; Zhao W
    Neuro Oncol; 2017 Jan; 19(1):31-42. PubMed ID: 27416954
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical relevance of BRAF status in glial and glioneuronal tumors: A systematic review.
    Sugiura Y; Nagaishi M
    J Clin Neurosci; 2019 Aug; 66():196-201. PubMed ID: 31147232
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A clinicopathologic study of diencephalic pediatric low-grade gliomas with BRAF V600 mutation.
    Ho CY; Mobley BC; Gordish-Dressman H; VandenBussche CJ; Mason GE; Bornhorst M; Esbenshade AJ; Tehrani M; Orr BA; LaFrance DR; Devaney JM; Meltzer BW; Hofherr SE; Burger PC; Packer RJ; Rodriguez FJ
    Acta Neuropathol; 2015 Oct; 130(4):575-85. PubMed ID: 26264609
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of the CD34 antigen in pleomorphic xanthoastrocytomas.
    Reifenberger G; Kaulich K; Wiestler OD; Blümcke I
    Acta Neuropathol; 2003 Apr; 105(4):358-64. PubMed ID: 12624789
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MGMT Promoter Methylation and BRAF V600E Mutations Are Helpful Markers to Discriminate Pleomorphic Xanthoastrocytoma from Giant Cell Glioblastoma.
    Lohkamp LN; Schinz M; Gehlhaar C; Guse K; Thomale UW; Vajkoczy P; Heppner FL; Koch A
    PLoS One; 2016; 11(6):e0156422. PubMed ID: 27253461
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.